%0 Journal Article %A Marika Watanabe %A Kimikazu Yakushijin %A Yohei Funakoshi %A Goh Ohji %A Hironori Sakai %A Wataru Hojo %A Miki Saeki %A Yuri Hirakawa %A Sakuya Matsumoto %A Rina Sakai %A Shigeki Nagao %A Akihito Kitao %A Yoshiharu Miyata %A Taiji Koyama %A Yasuyuki Saito %A Shinichiro Kawamoto %A Mitsuhiro Ito %A Tohru Murayama %A Hiroshi Matsuoka %A Hironobu Minami %T Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in Japanese patients after allogeneic stem cell transplantation %D 2021 %R 10.1101/2021.12.28.21268477 %J medRxiv %P 2021.12.28.21268477 %X Patients who have undergone hematopoietic stem cell transplantation (HSCT) for hematological disease experience high mortality when infected by coronavirus disease 2019 (COVID-19). However, the safety and efficacy of COVID-19 vaccine in HSCT patients remains to be investigated. We prospectively evaluated the safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine (Pfizer BioNTech) in 25 Japanese allogeneic HSCT patients in comparison with 19 healthy volunteers. While anti-S1 antibody titers in almost all healthy volunteers after the second dose were higher than the cut-off value reported previously, levels in HSCT patients after the second dose were diverse. Nineteen patients (76%) got seroconversion of anti-S1 IgG. Median optical density of antibody levels in HSCT patients with low IgG levels (< 600 mg/dL), steroid treatment, or low lymphocytes (< 1000 /μL) was significantly lower than that in the other HSCT patients. There were no serious adverse events (> Grade 3), no new development or exacerbation of graft-versus-host disease after vaccination. We concluded BNT162b2 mRNA vaccine is safe and effective in Japanese allogeneic HSCT patients.Competing Interest StatementHironobu Minami has received research grants and honoraria from Pfizer. Kimikazu Yakushijin has received honoraria from Pfizer. Hironori Sakai and Wataru Hojo are employed by Cellspect. The other authors declare no potential conflicts of interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics commitee of Kobe University Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. %U https://www.medrxiv.org/content/medrxiv/early/2021/12/29/2021.12.28.21268477.full.pdf